Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitut Pasteur
About this trial
In recent years, the global rise in obesity and type 2 diabetes has become a major public health issue. In New Caledonia, 38% of the adult population has a body mass index ≥30. At the same time, the prevalence of type 2 diabetes continues to rise steadily. The burden of these diseases does not affect communities uniformly. While known factors such as diet, physical activity, and socioeconomic conditions play a role, studies have demonstrated the involvement of the gut microbiota in the development of metabolic disorders, particularly obesity and insulin resistance. However, this area remains largely unexplored in New Caledonia and the Pacific.
Eligibility criteria
Qualifiers
Aged between 18 and 60 years.
Ability to understand and provide informed consent.
Ability and willingness to meet the required schedule and study interventions.
Willingness to share their community belonging
Disqualifiers
Treatment that may alter gastrointestinal motor function, acidity, microbial population, or immunosuppressants
Altered anatomy of the esophagus, stomach, small intestine, or large intestine due to gastrointestinal surgery (except appendectomy or cholecystectomy)
Chronic or acute inflammatory bowel disease or infections
Abdominal or pelvic radiation therapy or abdominal cancer, colorectal cancer
Trial design
Treatments tested in this trial
- 25 ml blood sample
- Urine sample
- Stools
- 40 ml blood sample
Treatment groups
270 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Institut Pasteur
Lead sponsor
RIKEN Center for Integrative Medical Sciences
Collaborator
Source ClinicalTrials.gov